Latest news

Ollin Biosciences takes aim at Roche with $100M and bold eye drug strategy

Ollin Biosciences takes aim at Roche with $100M and bold eye drug strategy

Eduardo Longoria
Daily Snap - 17. September 2025

Daily Snap - 17. September 2025

Joachim Eeckhout
Genmab axes ADC from $1.8B ProfoundBio buyout over safety concerns

Genmab axes ADC from $1.8B ProfoundBio buyout over safety concerns

Eduardo Longoria
Apollo's $15M eczema gamble pays off with promising phase 2 win

Apollo's $15M eczema gamble pays off with promising phase 2 win

Eduardo Longoria
Daily Snap - 16. September 2025

Daily Snap - 16. September 2025

Joachim Eeckhout
Novartis expands $5.7B bet on Monte Rosa’s protein-degrading drugs

Novartis expands $5.7B bet on Monte Rosa’s protein-degrading drugs

Eduardo Longoria
Lila Sciences raises $235M to scale AI-driven “scientific superintelligence” labs

Lila Sciences raises $235M to scale AI-driven “scientific superintelligence” labs

Eduardo Longoria
Daily Snap - 15. September 2025

Daily Snap - 15. September 2025

Joachim Eeckhout
Trump-era FDA moves to sideline expert drug reviews, raising alarm

Trump-era FDA moves to sideline expert drug reviews, raising alarm

Eduardo Longoria
Galimedix eyes phase 2 Alzheimer's trial after oral drug clears safety hurdle

Galimedix eyes phase 2 Alzheimer's trial after oral drug clears safety hurdle

Eduardo Longoria
Daily Snap - 12. September 2025

Daily Snap - 12. September 2025

Joachim Eeckhout
Revolution’s daraxonrasib heads to Phase III after strong PDAC trial results

Revolution’s daraxonrasib heads to Phase III after strong PDAC trial results

Eduardo Longoria
FirstBack
1718192021222324
Next Last